Pelcitoclax

Pelcitoclax (APG-1252) is a potent Bcl-2/Bcl-xl inhibitor with antineoplastic and pro-apoptotic effects[1].

Product Specifications

CAS Number

[1619923-36-2]

Product Name Alternative

APG-1252

UNSPSC

12352005

Target

Apoptosis; Bcl-2 Family

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/pelcitoclax.html

Purity

99.70

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(C1CCN(CC[C@@H](NC2=CC=C(S(=O)(NC3=CC=C(N4CCN(C5=CC(F)=CC(C6=C(C7=CC=C(Cl)C=C7)N(C(C)C)C(C)=C6S(=O)(C)=O)=C5)CC4)C=C3)=O)C=C2S(=O)(C(F)(F)F)=O)CSC8=CC=CC=C8)CC1)OCCCP(O)(O)=O

Molecular Formula

C57H66ClF4N6O11PS4

Molecular Weight

1281.85

References & Citations

[1]Hanjie Yi, et al. Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma. Cancer Med. 2020 Jun;9 (12) :4197-4206.